AMEX : BAL
-$0.18 (-0.29%)
| Source | Headline |
|---|---|
|
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study gurufocus.com - 2026-06-25 08:00:00 |